SCHEMBL5267360

SCHEMBL5267360

O=c1c(Cl)c(CN2CC=C(c3cc(Cl)ccc3OC(F)F)CC2)[nH]n1Cc1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39
PRKAG2 Q9UGJ0 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
KCNH2 Q12809 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRK1 P41145 1/20 0.37
MAPK1 P28482 1/20 0.36
DRD2 P14416 5/20 0.36
HTR1A P08908 3/20 0.36
SLC6A4 P31645 3/20 0.36
HTR7 P34969 3/20 0.36
HTR6 P50406 3/20 0.36
PDE4B Q07343 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
DRD4 P21917 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264560 0.85 PRKAB2 (0.45) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL4334582 0.78 KCNH2 (0.40) KCNH2MAPK1DRD2HTR1ASLC6A4
SCHEMBL4319823 0.68 PPARG (0.35) KCNH2DRD2HTR1A
SCHEMBL4319927 0.68 LMNA (0.43) KCNH2MEN1KMT2ACCNT1CDK9
SCHEMBL5262822 0.64 MAPT (0.44) MEN1KMT2ANPSR1
SCHEMBL5246497 0.64 OPRM1 (0.59) OPRM1OPRK1DRD2HTR1AHTR6
SCHEMBL4339476 0.63 CNR1 (0.53) HTR6
SCHEMBL4328972 0.63 KCNH2 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL5264814 0.62 MAPT (0.42) MEN1KMT2ANPSR1
SCHEMBL4333010 0.61 HTR2C (0.51) HTR7HTR6CCNT1CDK9SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed